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Owing to the lack of randomised controlled trials no standard of chemotherapy exists in the treatment of advanced biliary tract
carcinoma. 5-fluorouracil or gemcitabine is recommended based on small and predominately phase II trials. The aim of this analysis
was to analyse existing trials, even small and nonrandomised, and identify superior regimens. Chemotherapy trials published in English
from 1985 to July 2006 were analysed as well as ASCO abstracts from 1999 to 2006. Response rate (RR¼CRþPR), tumour control
rate (TCR¼CRþPRþSD), time to tumour progression (TTP), overall survival (OS), and toxicity were analysed. One hundred and
four trials comprising 112 trial arms and 2810 patients, thereof 634 responders and 1368 patients with tumour control were analysed.
Pooled RR and TCR were 22.6 and 57.3%, respectively. Significant correlations of RR and TCR with survival times were found.
Subgroup analysis showed superior RRs for gallbladder carcinoma (GBC) compared with cholangiocarcinoma, but shorter OS for
GBC. Furthermore, superior RRs and TCRs of gemcitabine and platinum containing regimens were found with highest RRs and TCRs
in the combination subgroup. Based on published results of predominately phase II trials, gemcitabine combined with platinum
compounds represents the provisional standard of chemotherapy in advanced biliary tract cancer, unless a new evidence-based
standard has been defined.
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Biliary tract carcinomas (BTC) are uncommon but highly fatal
malignancies in the United States and Europe. BTC comprise
gallbladder carcinoma (GBC) and cholangiocarcinoma (CC) (bile
duct cancer), which arise from the epithelial cells of the
intrahepatic and extrahepatic bile ducts. The anatomic location
of CC can be described as intrahepatic, distal extrahepatic, or hilar.
Lesions can be described as mass-forming, periductal or intra-
ductal, or as mixed mass-forming and periductal (Patel, 2006).
Approximately 5000 cases of GBC and 2500 cases of CC are
diagnosed annually in the USA (de Groen et al, 1999). The
incidence of CC (particularly, intrahepatic CC) has been rising
over the past two decades in the United States, United Kingdom,
and Australia (Rajagopalan et al, 2004). Worldwide, the highest
prevalence of GBC is seen in India, Pakistan, Ecuador, Israel,
Mexico, Chile, Japan, and among Native American women,
particularly those living in New Mexico. Mortality rates in these
areas can reach 5–10 times that in the United States (Lazcano-
Ponce et al, 2001; Randi et al, 2006). Worldwide, CC accounts for
3% of all gastrointestinal cancers and is the second commonest
primary hepatic tumour (Khan et al, 2005). Incidence of CC is
highest in Israel, Japan, among Native Americans, and in Southeast
Asia, where it can reach 87 per 100000 (Rajagopalan et al, 2004).
This indicates the global significance of both GBC and CC.
The reported incidence of ‘surprise’ or ‘incidental’ GBC varies
from 0.35 to 2% (Misra and Guleria, 2006). Even in patients
undergoing aggressive surgery, the general outcome of patients
with BTC has been disappointing. Five-year survival rates are
5-10% for GBC and 10–40% for CC (de Groen et al, 1999).
Unfortunately, most biliary tract carcinomas are diagnosed at
advanced stages when the tumour is unresectable. Median survival
of patients with advanced disease is in the range of only a few
months.
Owing to the lack of randomised phase III studies, there is no
standard regimen for palliative chemotherapy of GBC and CC.
Depending on the patient’s general condition best supportive care,
a clinical trial, 5-fluorouracil, or gemcitabine is recommended
according to guidelines of the National Comprehensive Cancer
Network.
The aim of this study was to extensively analyse existing data of
published clinical trials, even small and non-randomised, and, if
possible, identify superior regimens, which may represent a
standard of care of palliative chemotherapy in this disease.
METHODS
Data for this analysis were identified by searches of PubMed and
references from relevant articles using the search terms ‘biliary
tract neoplasms’, ‘bile duct neoplasms’, ‘cholangiocarcinoma’, and
‘gallbladder neoplasms’. Only papers reporting the results of
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schemotherapy trials published in English from January 1985 to
July 2006 were included. Abstracts from ASCO meetings presented
from 1999 to 2006 were included also. Trials of intra-arterial
hepatic chemotherapy or of chemoradiotherapy were excluded.
For inclusion of a trial in the analysis, the number of patients
(included, treated, or evaluable) and the response rate
(RR¼CRþPR) were required at least. Furthermore, tumour
control rate (TCR¼CRþPRþSD), time to tumour progression
(TTP), and overall survival (OS) were recorded if available. In
trials with more than one treatment arm, arms were analysed
separately as single-arm trials. All trials included were analysed
independent of the tumour classification for BTC. In addition,
subgroup analysis was performed for GBC-only and CC-only for
trials with sufficient data.
For subgroup analysis results of the trials were compared and
tested nonparametrically (Mann–Whitney, Kruskal–Wallis).
Furthermore, RR and TCR data were pooled by summarising the
number of patients of the trials. For example, a pooled RR was
computed as the sum of the responders of a subgroup divided by
the sum of the patients of this subgroup. Ninety-five per cent
confidence interval (CI) was calculated by the method of Clopper
and Pearson. Proportions (e.g., pooled RRs) were compared by
z-test. Nonparametric Correlation was tested according to Spearman.
RESULTS
One hundred and four trials comprising of 112 trial arms were
included in this analysis (for references see Appendix A). Only
three were randomised trials, thereof two phase II (Kornek et al,
2004; Ducreux et al, 2005) and one phase III (Rao et al, 2005). No
appropriate trial could be identified as published 1992 or earlier
(limited to 1985). Seventeen (15%) trials were published from 1993
to 1999, whereas 95 (85%) trials were published from 2000 to July
2006. The 112 trials analysed comprise a total of 2810 patients
treated.
The number of patients per trial ranged from 5 to 65 resulting in
a mean number of patients per trial of 25.1 with a small range in
various subgroups. The mean number of patients per trial (or per
subgroup of a trial) for GBC-only and CC-only was smaller with
16.7 and 19.6, respectively.
Among all 2810 patients (25.1 per trial) analysed, 634 responders
(5.7 per trial) were observed resulting in a pooled RR of 22.6%
(95% CI 21.0–24.2%, n¼2810). The RRs of all trials analysed
sorted by the number of patients are shown in Figure 1. The RR of
nine (8%) trials was above the upper limit of the 95% CI of 22.6%
(Figure 1, ‘high’ RR). Twenty two (20%) trials had RRs below the
lower limit of the 95% CI of 22.6% (‘low’ RR) and 81 (72%)
trials had RRs in the range of the 95% CI (‘middle’ RR). The nine
‘high’ RR trials evaluated gemcitabine plus platinum compounds
(n¼5), fluoropyrimidines plus platinum compounds (n¼3), and
gemcitabine alone (n¼1). Among the 22 trials with ‘low’ RRs are
trials evaluating docetaxel, paclitaxel, irinotecan, gemcitabine, and
fluoropyrimidines as well as new drugs (erlotinib, lapatinib,
exatecan, dolastatin, lanreotide). Figure 2 shows the RR and its
95% CI of all trials analysed sorted by the RR.
Ninety six trials reported stable disease or TCR data. These 96
trials comprise 2386 patients, thereof 1368 patients achieving
tumour control (14.3 patients with tumour control per trial)
resulting in a pooled TCR of 57.3% (95% CI 55.3–59.3%,
n¼2386).
Survival
The median TTP and OS for all patients was 4.1 months (60 trials,
1543 patients) and 8.2 months (82 trials, 2197 patients),
respectively. There was a highly significant correlation between
RR and TCR (r¼0.59, P¼0.000), RR and TTP (r¼0.52,
P¼0.000), TCR and TTP (r¼0.66, P¼0.000), and TTP and OS
(Figure 3A). Furthermore, a significant weak correlation between
RR and OS as well as TCR and OS was found (Figures 3B and C).
Regression equation showed a 10% increment in RR correspond-
ing to an 8% increase of TCR, a 0.7-month increase of TTP, and a
0.6-month increase of OS. A 10% increment in TCR corresponded
to a 0.7-month increase of TTP, a 0.7-month increase of OS,
whereas a 1-month increase in TTP corresponded to a 1.3-month
increase of OS.
Subgroups
The RR of trials (subgroups) of patients with GBC was higher
compared with CC (number of patients 500 vs 471, pooled RR 34.4
vs 20.2%, P¼0.000; median RR of trials 35.5 vs 17.7%, P¼0.008).
For the TCR, there was no significant difference between GBC and
CC (pooled TCR 60.5 vs 59.7%, P¼0.904; median RR of trials 60.0
vs 55.0%, P¼0.784). In contrast, the OS was significantly longer
in trials (subgroups) of patients with CC compared with GBC
(median 9.3 vs 7.2 months, P¼0.048).
Comparison of regimens containing one or two drugs showed
significant superiority of two drug combinations compared with
monotherapy concerning RR (number of patients 1499 vs 971,
pooled RR 28.0 vs 15.3%, P¼0.000; median RR of trials 25.8 vs
11.8%, P¼0.000), TCR (pooled TCR 61.0 vs 50.4%, P¼0.000;
median TCR of trials 60.0 vs 48.0%, P¼0.003), and TTP (median
4.4 vs 3.4 months, P¼0.015) with a trend for OS (median 9.3 vs
7.5 months, P¼0.061). Polychemotherapy (three or more drug
regimens) resulted in a lower RR compared with two drug
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Figure 1 Response rates of all trials analysed sorted by the number of
patients. Full papers are indicated by black rhombi and ASCO abstracts by
empty triangles. The horizontal grey line represents the pooled response
rate of all patients (22.6%). The limits of the 95% CI of the overall pooled
RR are shown by doted lines.
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Figure 2 Response rate and 95% CI of all trials analysed sorted by the
RR. The horizontal grey represents the pooled RR of all patients (22.6%).
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scombinations (number of patients 340 vs 1499, pooled RR 19.1 vs
28.0%, P¼0.000; median RR of trials 19.2 vs 25.8%, P¼0.065) but
no difference in OS (median 9.0 vs 9.3 months). Comparison of
polychemotherapy with monotherapy showed higher TCR (pooled
TCR 58.9 vs 50.4%, P¼0.028; median TCR of trials 62.8 vs 48.0%,
P¼0.098), longer TTP (median 5.2 vs 3.4 months, P¼0.016), and
OS (median 9.0 vs 7.5 months, P¼0.086) of multiple drug
combinations.
Further subgroup analysis focused on cytotoxic agents. Sub-
groups of patients treated with regimens containing a particular
drug were compared with all other patients, who were treated with
regimens, that did not contain this particular drug, regardless
of other drugs. Subgroups were defined by fluoropyrimidines
(fluorouracil, capecitabine, tegafur), gemcitabine, platinum com-
pounds (cisplatin, oxaliplatin, carboplatin), anthracyclines (adria-
mycin, epirubicin), mitomycin C, taxanes (paclitaxel, docetaxel),
and irinotecan. RR and TCR were analysed by pooling all patients
(bars with 95% CI) as well as all trials (boxplots) (Figure 4A–D).
Results of treatment with fluoropyrimidines were very similar
to the results of all fluoropyrimidine-free regimens and may
represent the results of all patients and all trials analysed. In
contrast, treatment with gemcitabine as well as with platinum
compounds resulted consistently in highly significant superior RRs
and TCRs compared with gemcitabine-free as well as to platinum-
free combinations (Figure 4A–D). In contrast, beside from a trend
for a longer TTP of the gemcitabine subgroup (4.6 vs 3.7 months,
P¼0.085), differences in survival times were small (platin vs no
platin: TTP and OS 0.7 months each) and not significant.
For further investigation of the effects of fluoropyrimidines,
gemcitabine, and platinum compounds, subgroups defined by
treatment with these three agents and all combinations (regardless
of other drugs) were analysed considering RR and TCR for all
patients and all trials (Figure 5A–D). As shown in Figure 5A–B the
RR of treatment with gemcitabine was not significantly higher
compared with fluoropyrimidines. The addition of platinum
compounds increased the RR of fluoropyrimidines as well as of
gemcitabine. The increase of the RR by the addition of platinum
compounds to gemcitabine was double the increase of the addition
to fluoropyrimidines (17.0 vs 8.7%). The increase of the RR by the
addition of gemcitabine to fluoropyrimidines was similar to the
addition of platinum compounds to fluoropyrimidines.
In contrast to analysation for RR, pooled TCR of the
gemcitabine subgroup was significantly higher compared with
fluoropyrimidines (P¼0.024, Figure 5C). The addition of platinum
compounds to fluoropyrimidines and gemcitabine increased the
TCRs, but the difference was significant for the pooled TCR of the
fluoropyrimidine subgroup only (9.7%, P¼0.006). Just as for RRs,
TCR was highest in the gemcitabine–platinum combination
subgroup. Compared with the fluoropyrimidines subgroup the
difference was significant for the pooled TCR (P¼0.000,
Figure 5C) as well as for the median TCR (P¼0.025, Figure 5D).
There was a trend for a longer TTP in the gemcitabine–platinum
combination subgroup compared with the fluoropyrimidines–
platinum combination subgroup (5.5 vs 3.7 months, P¼0.072, 21
trials). All other differences of TTP and OS between subgroups
were small and not statistically significant.
There were only a few trials evaluating new drugs, such as
erlotinib, lapatinib, dolastatin, exatecan, rebeccamycin (one trial
each, monotherapy), and raltitrexed (two trials, combination with
gemcitabine and cisplatin/epirubicin, respectively). For separate
analysis of a new agent subgroup, separately the numbers of trials
and patients are too low. Monotherapy trials of new agents are
subsumed in the n/n subgroup (neither fluoropyrimidine nor
gemcitabine without platinum compounds, Figure 5A–D).
Statistics
Only a minority of the trials reported statistical considerations
such as sample size calculation, null and alternative hypothesis,
significance level, and power. The preferred test design was the
Simon two-stage design. Significance level (alpha) was mostly 0.05
(range 0.03–0.10) and the power was mostly 80% (range 80% –
95%). The null hypotheses tested ranged from an RR of p0 p5t o
p20% with alternative hypotheses between an RR of pAX15 and
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Figure 3 (A–C) Charts showing the correlation between RR, TCR, TTP and OS.
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sX40%. The number of trials analysed in this study, which would
have been negative, if tested with RR or TCR as primary end point
against different alternative hypotheses pA with different powers,
are listed in Table 1A, whereas Table 1B shows the number of
trials, which would have been positive if tested against different
null hypotheses p0 with different significance levels (alpha).
DISCUSSION
This pooled analysis of all published clinical trials since 1985
showed that chemotherapy with gemcitabine combined with
cisplatin or oxaliplatin increases RR and TCR in GBC and CC.
Our findings provide best possible evidence that this combination
chemotherapy may improve survival in these diseases.
This is the first systematic review including a comprehensive
statistical analysis of advanced GBC and CC. One hundred and
four trials comprising 112 trial arms were included in this analysis.
Pooled RR of all patients was 22.6% (95% CI 21.0–24.2%). RRs of
single trials range from 0% to more than 80% and the median RR
was 20.0% with a first and third quartile of 11.5 and 33.2%,
respectively. In other words, one-fourth of all trials reported RRs
less than or equal to 11.5% and another fourth RRs greater than or
equal to 33.2%. The aims of this analysis were to identifiy superior
regimens among this extreme range of RRs and thus to provide a
standard of chemotherapy in advanced BTC, even based on phase
II trials before the background of missing phase III trials.
The cochrane collaboration published a protocol to assess the
beneficial and harmful effects of chemotherapy for gallbladder
cancer (Pandey and Krishnan, 2004). Initially, the review was
All patients, n=2810
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Figure 4 (A–D) Fluoro: fluoropyrimidines (fluorouracil, capecitabine, tegafur); Gem: gemcitabine; Platin: platinum compounds (cisplatin, oxaliplatin,
carboplatin); Anthra: anthracyclines (adriamycin, epirubicin); MMC: mitomycin C; Taxan: taxanes (paclitaxel, docetaxel), Irino: irinotecan. (A) Pooled RRs
(RR¼CRþPR) and 95% CIs of all patients included in the analysis and of subgroups of patients, defined by treatment with regimens containing a particular
drug regardless of other drugs. The height of the bars correlates with the number of patients. The P-values apply to the comparison of a subgroup, defined
by a particular drug vs all other patients, which were not treated with this drug (e.g., patients treated with gemcitabine or gemcitabine-containing
combinations vs patients treated with gemcitabine-free regimens). The RRs of the comparison subgroups are not shown. The vertical grey line represents the
pooled RR of all patients (pts, 22.6%). (B) Boxplots of the RRs of all trials and of subgroups, defined by a particular drug. The height of the boxplots
correlates with the number of trials. P-values for subgroup comparison as in Figure 3A. The vertical grey line represents the median RR of all trials (20.0%).
For subgroups consisting of less than five trials, results of single trial are shown and no boxplots are provided. (C) Pooled TCRs (TCR¼CRþPRþSD) and
95% CIs as in Figure 3A. The vertical grey line represents the pooled TCR of all patients (57.3%). (D) Boxplots of the TCRs as in Figure 3B. The vertical grey
line represents the median TCR of all trials (59.6%).
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sexpected to be published in Issue 4, 2005. However, owing to the
principles of the cochrane collaboration, this review should
address randomised trials evaluating chemotherapy vs placebo/
no chemotherapy and one type of chemotherapy vs another type of
chemotherapy. As almost no randomised trials exist, this cochrane
review will not be finished at all.
Guidelines for the treatment of CC have been published 2002 by
the BASL (British Association for the Study of the Liver) (Khan
et al, 2002). Consensus conclusion from predominately phase II
trials suggest: (i) RRs is of 5-fluorouracil based and (older) single
agents is 10–20%, (ii) RRs of newer single agents, such as
gemcitabine, vary from 20 to 30%, (iii) RRs of recent phase II
combinations vary from 20 to 40%, and (iv) gemcitabine in
combination with cisplatin shows 30–50% RRs. The results of the
present analysis are somewhat different, but agree in principle
concerning the combination of gemcitabine with cisplatin: (i) more
than a half of fluoropyrimidine-based trials reported RRs of more
than 20%, (ii) more than a half of single-agent gemcitabine trials
and nearly all trials of newer single agents reported RRs of less
than 20%, (iii) about 40% of combination trials reported RRs of
20% or less, and (iv) the middle half of gemcitabine plus platinum
combinations results in RRs between 26 and 50%, that is, one-
quarter of this combination trials reported RRs of 50% or greater
(Figure 5B).
Three randomised trials, thereof only one phase III, were
included in the present study. The 40955 EORTC phase II trial
compared high-dose 5-FU with a combination of cisplatin, 5-FU,
and folinic acid (Ducreux et al, 2005). The RR was higher in the
combination arm (19 vs 7%), but there was no difference
concerning disease stabilisation and toxicity was increased. Based
on potential drug synergy a phase II trial compared two
experimental arms: MMC combined with biweekly high-dose
gemcitabine vs MMC combined with capecitabine (Kornek et al,
2004). The latter combination resulted in higher RR (31 vs 20%),
TTP (5.3 vs 4.2 months), and OS (9.3 vs 6.7 months). A statistical
comparison of the two groups including P-values was not
published. The authors conclude that MMC combined with
capecitabine seems to be superior, and further evaluation seems
warranted. The only phase III trial of the present analysis
compared etoposide, 5-FU, and folinic acid with epirubicin,
cisplatin, and 5-FU (ECF) (Rao et al, 2005). As a result of poor
recruitment (n¼54) the trial was underpowered to detect a
significant difference in OS. The ECF regimen was associated with
less toxicity, but in conclusion, based on these data it is not
possible to define a reference regimen for advanced BTC.
Owing to the lack of randomised phase III trials, there is a need
to define treatment standards on predominately phase II trials.
For this reason, we will necessarily act on imperfect evidence.
This issue was discussed recently (Djulbegovic et al, 2005). For
a treatment goal of prolongation of survival by days to months,
highest standards of experimental evidence (well-designed and
large-scale conducted RCTs) were proposed. The increasing
number of publications of chemotherapy trials in this disease
emphasise the need of a new standard beyond 5-FU. Hopefully, the
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Figure 5 (A–D) Fluoro: n/n: neither Fluoro nor Gem; Fluoro:
fluoropyrimidines (fluorouracil, capecitabine, tegafur); Gem: gemcitabine;
P: platinum compounds (cisplatin, oxaliplatin, carboplatin). (A) Pooled RRs
(RR¼CRþPR) and 95% CIs of subgroups of patients, defined by
treatment with fluoropyrimidines, gemcitabine, and platinum compounds,
regardless of other drugs. The height of the bars correlates with the
number of patients. The vertical grey line represents the pooled RR of the
Fluoro subgroup (17.1%). The Fluoro-Gem-P subgroup consists of only
eight patients and is therefore not shown. Additional P-values: Fluoro vs
Gem-P: 0.000; n/n vs all other subgroups: 0.000; n/n-P vs Gem-P: 0.012. (B)
Boxplots of RRs of subgroups of trials, defined by treatment with
fluoropyrimidines, gemcitabine, and platinum compounds. The height of
he boxplots correlates with the number of trials. The vertical grey line
represents the median RR of the Fluoro subgroup (19.2%). The Fluoro-
Gem-P subgroup consists of only one trial and is therefore not shown. For
subgroups consisting of less than five trials, results of single trial are shown
and no boxplots are provided. Additional P-values: Fluoro vs Gem-P: 0.000;
Fluoro-P vs Gem: 0.033; n/n vs all other subgroups: p0.002; n/n-P vs Gem-
P: 0.042. (C) Pooled TCRs (TCR¼CRþPRþSD) and 95% CIs of
subgroups of patients as in Figure 4A. The vertical grey line represents the
pooled TCR of the Fluoro subgroup (50.9%). *P-value in comparison to the
Fluoro subgroup. Additional P-values: n/n vs all other subgroups: 0.000. (D)
Boxplots of TCRs of subgroups of trials as in Figure 4C. The vertical grey
line represents the median RR of the Fluoro subgroup (55.0%). Additional
P-values: n/n vs all other subgroups: p0.003.
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sincreasing number of publications will be followed by an
increasing quality of the trials. Only a minority of the trials
analysed published statistical considerations and frequently results
were subsumed as being promising. For well designed phase II
trials it is necessary to prospectively define a null hypothesis, an
alternative hypothesis, the significance level (alpha), and the power
(Tables 1A, B). By the use of the Simon MinMax two-stage design
and reasonable parameters, the number of patients of a phase II
trial will not exceed a total of 40 patients and 25 patients for the
first stage.
The longer TTP and OS of multiple drug combinations may be
due to more strict inclusion criteria of potentially more toxic
regimens and may indicate selection bias. Furthermore, the
proportion of patients with different localisations of their cancers
may contribute to selection bias, as the present analysis showed
higher RRs but shorter OS of GBC compared with CC.
Subgroup analysis concerning the three most important drugs
demonstrated that gemcitabine alone is not superior to fluoro-
pyrimidines. Platinum compounds increase the activity of both
fluoropyrimidines and gemcitabine. The increase of the addition of
platinum compounds to gemcitabine is greater compared with the
addition to fluoropyrimidines. Synergism of cisplatin and gemci-
tabine has been demonstrated in cell lines and is based on direct
inhibitory effect of gemcitabine on the repair of cisplatin
interstrand adducts and interstrand crosslinks (van Moorsel
et al, 1999; Moufarij et al, 2003).
The present analysis demonstrated gemcitabine combined with
platinum compounds superior concerning both RR and TCR. As
RR and TCR significantly correlate with survival times (TTP and
OS), RR and TCR represent a meaningful surrogate in BTC. In
patients with colorectal cancer a meta-analysis of randomised
phase III trials demonstrated highly significant correlation
between RR and TTP, TTP and OS, and RR and OS (Louvet
et al, 2001). A 10% RR increment corresponded to a 1-month
increase in TTP and a 0.9-month increase in OS, whereas a 1-
month increase in TTP corresponded to a 0.7-month increase
of OS in colorectal cancer patients on first-line treatment.
Our findings in BTC demonstrated a 10% RR increase correspond-
ing to a 0.7-month increase in TTP and a 0.6-month increase in
OS, whereas a 1-month increase in TTP corresponded to a
1.3-month increase of OS. Consequently, the data of highest
experimental evidence in colorectal cancer confirm the results
of our pooled analysis of clinical and predominately phase II trials
in BTC.
The evidence level of this pooled analysis is limited as discussed
above and it remains unclear which platinum compound is
optimal and what schedule of administration should be used.
Therefore, it is essential to perform randomised trials, such as the
UK National Cancer Research Institute ABC-02 trial, to evaluate
the definite role of platinum compounds in combination with
gemcitabine compared with gemcitabine alone. This and similar
trials are needed to establish reference regimens for this disease.
In conclusion, we suggest gemcitabine combined with cisplatin
or oxaliplatin as the most active, and therefore a provisional
standard regimen in BTC until a new evidence-based standard is
defined.
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